Pearsanta, a subsidiary of Aditxt, has recently acquired the Mitomic testing platform from MDNA Life Sciences. The transaction, valued at approximately $25 million, is a strategic expansion for Pearsanta, enhancing its capabilities in early disease and cancer detection, particularly in women’s health, focusing on conditions such as endometriosis and ovarian cancer. The Mitomic technology utilizes mitochondrial DNA (mtDNA) to detect diseases at…
In a stride towards non-surgical endometriosis diagnosis, Hera Biotech has announced its impending acquisition of endometriosis diagnostic assets from Scailyte, a company active in single-cell and AI-driven biomarker discovery. This acquisition marks a notable consolidation in the tissue-based diagnostic landscape for endometriosis, a prevalent condition contributing to a significant portion of female infertility and characterized by severe pain due to the abnormal…
Endometriosis, a debilitating disease affecting nearly 190 million women globally, has long been under-recognized and inadequately treated. The need for innovation in the field is evident, and a recent initiative from BioInnovation Institute (BII)‘s Bio Studio program might be a breakthrough. The CurE-me project, under the leadership of Professor Hugo Vankelecom from KU Leuven, seeks to unearth new therapeutic drugs to tackle…
Health Canada has granted approval to MYFEMBREE for the management of pain related to endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The drug, a joint venture between Sumitomo Pharma Canada and Pfizer Canada, is an oral combination therapy meant to be taken once daily. Endometriosis and uterine fibroids are serious health issues affecting a significant portion of…
In an advancement that could change the landscape of endometriosis treatment, pharmaceutical giants Gedeon Richter and Sumitomo Pharma recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for RYEQO. The drug, initially approved for the treatment of uterine fibroids, is on track to receive European Commission (EC) approval for the…
Danish biotech startup FimmCyte is joining BioInnovation Institute’s (BII) Venture House, a program designed to further support former BII Venture Lab companies in their next phase of growth. As part of the Venture House Program FimmCyte will receive a convertible loan of €1.3M in addition to the €500K the company received during its participation in BII Venture Lab. FimmCyte is committed to…
Berlin-based startup Hale has secured €350K in pre-seed funding to redefine women’s pain management. Founded in 2022 by Gaia Salizzoni and Vittoria Brolis, Hale is on a mission to revolutionize patient care through a home-care management app designed to guide genito-pelvic patients throughout their health journey. With a focus on scientific evidence, data integration, and collaboration with existing healthcare systems, Hale aims…
French biotech company Ziwig has achieved a significant breakthrough in the field of endometriosis diagnosis with the validation of their Ziwig Endotest as a highly effective diagnostic tool. The study, published in the renowned New England Journal of Medicine (NEJM) Evidence, confirms the performance and reproducibility of Ziwig Endotest, boasting sensitivity and specificity rates exceeding 95%. This non-invasive test offers an alternative…
